18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)

被引：0
|
作者：
Ziemssen, Tjalf [1 ]
Lorente, Maria Diaz [2 ]
Vollmar, Patrick [2 ]
Meergans, Matthias [3 ]
Tracik, Ferenc Mark [2 ]
Kempcke, Raimar [4 ]
van Lokven, Tom [2 ]
机构：
[1] Univ Clin Dresden, MS Ctr, Dresden, Germany
[2] Novartis Pharma GmbH, Nurnberg, Germany
[3] Novartis Pharma GmbH, Basel, Switzerland
[4] Univ Clin Dresden, Dresden, Germany
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P01185
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long-term effectiveness of fingolimod in multiple sclerosis patients treated in the routine care of Greece: results of the 'DIAMOND' non-interventional, prospective, observational study
    Mitsikostas, D. D.
    Zafeiropoulou, E.
    Iliopoulos, I.
    Fakas, N.
    Thomaides, T.
    Maltezou, M.
    Grigoriadis, N.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 900 - 900
  • [32] Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study
    Kappos, Ludwig
    Radue, Ernst-Wilhelm
    O'Connor, Paul
    Polman, Chris
    Hohlfeld, Reinhard
    Calabresi, Peter
    Selmaj, Krzysztof
    Agoropoulou, Catherine
    Jin, James
    Zhang-Auberson, Lixin
    Francis, Gordon
    NEUROLOGY, 2012, 78
  • [33] Long-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE study design
    Coustans, M.
    Debouverie, M.
    Kobelt, G.
    Lebrun-Frenay, C.
    Leray, E.
    Papeix, C.
    Visy, J. M.
    Willemin, L.
    Allaf, B.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 764 - 764
  • [34] Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Pozzilli, C.
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S439 - S439
  • [35] Safety profile of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: long-term interim results from the ENDORSE extension study
    Pozzilli, C.
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Zhang, R.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Gold, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 678 - 678
  • [36] Long-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE two-year results
    Lebrun-Frenay, C.
    Papeix, C.
    Kobelt, G.
    Visy, J-M.
    Coustans, M.
    Debouverie, M.
    Lamy, F.
    Chouette, I.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 904 - 904
  • [37] Long-term efficacy, safety, tolerability and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France: VIRGILE one-year results
    Papeix, C.
    Lebrun-Frenay, C.
    Leray, E.
    Kobelt, G.
    Visy, J. M.
    Coustans, M.
    Debouverie, M.
    Aly, S.
    Chouette, I.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 649 - 650
  • [38] Long-term efficacy, safety, tolerability, and quality of life with fingolimod treatment in patients with multiple sclerosis in real-world settings in France-VIRGILE study design
    Coustans, M.
    Debouverie, M.
    Kobelt, G.
    LebrunFrenay, C.
    Leray, E.
    Papeix, C.
    Visy, J. M.
    Willemin, L.
    Allaf, B.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP23 - NP23
  • [39] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Oh, J.
    Syed, S.
    Orogun, L.
    Xu, Z.
    Turner, T. J.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
  • [40] Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
    Gold, Ralf
    Arnold, Douglas L.
    Bar-Or, Amit
    Fox, Robert J.
    Kappos, Ludwig
    Mokliatchouk, Oksana
    Jiang, Xiaotong
    Lyons, Jennifer
    Kapadia, Shivani
    Miller, Catherine
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 801 - 816
12345